Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilutamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 15/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilutamide SCHEMBL1462011 | 1.00 | AR (1.00) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL29351021 | 1.00 | AR (1.00) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL28562851 | 0.99 | AR (0.98) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL20695037 | 0.94 | AR (0.89) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL5579273 | 0.94 | AR (0.89) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL10324758 | 0.90 | AR (0.81) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL8407306 | 0.88 | AR (0.78) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL5537957 | 0.88 | AR (0.77) | ARLMNASMN1; SMN2MEN1TP53 | |
| SCHEMBL629458 | 0.85 | AR (0.74) | ARLMNASMN1; SMN2MEN1TP53 | |
| Nilutamide SCHEMBL115340 | 0.85 | AR (0.73) | ARLMNASMN1; SMN2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 67036 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4467200-B1 | EZH2 INHIBITION THERAPIES FOR THE TREATMENT OF ANDROGEN RECEPTOR MUTATED PROSTATE CANCERS | CONSTELLATION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| CN-122070133-A | Pharmaceutical compositions containing androgen receptor inhibitors/antagonists, methods and uses | 苏州开拓药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260125761-A1 | PREDICTION OF AN OUTCOME OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IN A PROSTATE CANCER SUBJECT | KONINKLIJKE PHILIPS NV (NL) | 2026-05-07 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-4775660-A | Treatment of breast cancer by combination therapy | LABRIE FERNAND (CA) | 1988-10-04 | — | — | US | claimed |
| US-4760053-A | Combination therapy for selected sex steroid dependent cancers | LABRIE FERNAND (CA) | 1988-07-26 | — | — | US | claimed |
| WO-1988003404-A1 | APPLICATION OF 1-(3'TRIFLUOROMETHYL 4'-NITROPHENYL) 4,4-DIMETHYL IMIDAZOLINE 2,5-DIONE IN THE TREATMENT OF HORMONE-DEPENDENT CANCERS OTHER THAN CANCER OF THE PROSTATE | ROUSSEL-UCLAF (FR) | 1988-05-19 | — | — | WO | claimed |
| US-4745102-A | Novel treatment method | ROUSSEL UCLAF (FR) | 1988-05-17 | — | — | US | claimed |
| US-4684635-A | SEBACEOUS GLAND HYPERTROPHY, HIRSUTISM | Orentreich, Norman (US) | 1987-08-04 | — | — | US | claimed |
| US-4659695-A | Method of treatment of prostate cancer | LABRIE FERNAND (CA) | 1987-04-21 | — | — | US | claimed |
| EP-0195015-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS. | LABRIE FERNAND (CA) | 1986-09-24 | — | — | EP | claimed |
| WO-1986001105-A1 | PHARMACEUTICAL COMPOSITION FOR COMBINATION THERAPY OF HORMONE DEPENDENT CANCERS | LABRIE FERNAND (CA) | 1986-02-27 | — | — | WO | claimed |
| US-4472382-A | Treatment method | ROUSSEL UCLAF (FR) | 1984-09-18 | — | — | US | claimed |
| US-4097578-A | ANTIANDROGENS | ROUSSEL UCLAF (FR) | 1978-06-27 | — | — | US | claimed |